Peter Senter
PhD
Senior Vice President
👥Biography 个人简介
Peter Senter developed the linker-drug technology underpinning the auristatin-based antibody-drug conjugate platform at Seattle Genetics. His work on maleimide linkers and the MMAE payload enabled development of brentuximab vedotin, enfortumab vedotin, and other FDA-approved ADCs. He has contributed to the chemistry of site-specific conjugation and cleavable linker design that enabled modern ADC precision oncology.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Peter Senter 的研究动态
Follow Peter Senter's research updates
留下邮箱，当我们发布与 Peter Senter（Seagen / Pfizer Oncology）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment